Wang Likui1, Wang Hong, Zhang Shuwen. 1. Department of Infection, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. kui_li2008@yahoo.com.cn
Abstract
OBJECTIVE: Osteopontin (OPN) is a phosphorylated glycoprotein which is associated with tumor progression, development, and metastasis. Recently, it has been reported that OPN is highly upregulated in a variety of human malignancies. The aim of this study is to investigate the clinical significance of OPN mRNA expression in colorectal cancer (CRC). MATERIAL AND METHODS: Conventional reverse transcription polymerase chain reaction (RT-PCR) and Western blot assays were performed to detect the expression of OPN mRNA and protein in human CRC cell lines and normal cell line. Real-time quantitative RT-PCR assay was performed to analyze the expression of OPN mRNA in 82 CRC tissue samples and corresponding non-tumor tissues. Immunohistochemistry was also performed to detect the expression of OPN protein in above tissues. Finally, the correlation between the status of OPN mRNA expression and clinicopathological factors and clinical outcome was evaluated. RESULTS: Compared with normal human intestinal epithelial cell line, human CRC cell lines showed high level of OPN gene expression at both transcriptional and translational levels. Moreover, the results of real-time quantitative RT-PCR and immunohistochemistry showed that the expression levels of OPN mRNA and protein in tumor tissues were significantly higher than those in the corresponding non-tumor tissues (P < 0.001). The expression level of OPN mRNA was significantly correlated with lymph node metastasis, lymphatic or venous invasion, and TNM stage (P = 0.0033, 0.0061, 0.0008, and 0.0012, respectively). Moreover, we also observed that the disease-free and overall survival rates in patients with high OPN mRNA expression were significantly shorter than those in patients with low OPN mRNA expression (P = 0.0047 and 0.0125). Additionally, the status of OPN mRNA expression was an independent prognostic factor for the prognosis of CRC patients (P = 0.008; RR, 2.775; 95% confidence interval, 2.334-3.811). CONCLUSION: OPN might play an important role in CRC progression and the status of OPN mRNA expression could be a novel prognostic molecular marker for CRC patients.
OBJECTIVE:Osteopontin (OPN) is a phosphorylated glycoprotein which is associated with tumor progression, development, and metastasis. Recently, it has been reported that OPN is highly upregulated in a variety of humanmalignancies. The aim of this study is to investigate the clinical significance of OPN mRNA expression in colorectal cancer (CRC). MATERIAL AND METHODS: Conventional reverse transcription polymerase chain reaction (RT-PCR) and Western blot assays were performed to detect the expression of OPN mRNA and protein in human CRC cell lines and normal cell line. Real-time quantitative RT-PCR assay was performed to analyze the expression of OPN mRNA in 82 CRC tissue samples and corresponding non-tumor tissues. Immunohistochemistry was also performed to detect the expression of OPN protein in above tissues. Finally, the correlation between the status of OPN mRNA expression and clinicopathological factors and clinical outcome was evaluated. RESULTS: Compared with normal human intestinal epithelial cell line, human CRC cell lines showed high level of OPN gene expression at both transcriptional and translational levels. Moreover, the results of real-time quantitative RT-PCR and immunohistochemistry showed that the expression levels of OPN mRNA and protein in tumor tissues were significantly higher than those in the corresponding non-tumor tissues (P < 0.001). The expression level of OPN mRNA was significantly correlated with lymph node metastasis, lymphatic or venous invasion, and TNM stage (P = 0.0033, 0.0061, 0.0008, and 0.0012, respectively). Moreover, we also observed that the disease-free and overall survival rates in patients with high OPN mRNA expression were significantly shorter than those in patients with low OPN mRNA expression (P = 0.0047 and 0.0125). Additionally, the status of OPN mRNA expression was an independent prognostic factor for the prognosis of CRC patients (P = 0.008; RR, 2.775; 95% confidence interval, 2.334-3.811). CONCLUSION:OPN might play an important role in CRC progression and the status of OPN mRNA expression could be a novel prognostic molecular marker for CRC patients.
Authors: Philip Y Wai; Zhiyong Mi; Hongtao Guo; Shiva Sarraf-Yazdi; Chengjiang Gao; Junping Wei; Carlos E Marroquin; Bryan Clary; Paul C Kuo Journal: Carcinogenesis Date: 2005-01-20 Impact factor: 4.944
Authors: Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo Journal: Mol Ther Date: 2008-11-04 Impact factor: 11.454
Authors: Franziska Rohde; Caroline Rimkus; Jan Friederichs; Robert Rosenberg; Carmen Marthen; Dietrich Doll; Bernhard Holzmann; Jörg-Rüdiger Siewert; Klaus-Peter Janssen Journal: Int J Cancer Date: 2007-10-15 Impact factor: 7.396
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Yue Qiu; Yuan Hu; Zuo-Yang Zhang; Lei Ye; Fei-Hong Xu; Marion E Schneider; Xue-Ling Ma; Yi-Xin Du; Xian-Bo Zuo; Fu-Sheng Zhou; Gang Chen; Xu-Shi Xie; Yan Zhang; Hong-Zhen Xia; Ji-Feng Wu; Wei-Dong Du Journal: J Cancer Res Clin Oncol Date: 2014-07-10 Impact factor: 4.553
Authors: Dimitrios Pectasides; George Papaxoinis; Konstantine T Kalogeras; Anastasia G Eleftheraki; Ioannis Xanthakis; Thomas Makatsoris; Epaminondas Samantas; Ioannis Varthalitis; Pavlos Papakostas; Nikitas Nikitas; Christos N Papandreou; George Pentheroudakis; Eleni Timotheadou; Angelos Koutras; Joseph Sgouros; Dimitrios Bafaloukos; George Klouvas; Theofanis Economopoulos; Konstantinos N Syrigos; George Fountzilas Journal: BMC Cancer Date: 2012-06-29 Impact factor: 4.430